Exhibit 11.1 ARONEX PHARMACEUTICALS, INC. Statement Regarding Computation of Per Share Earnings The following reflects the information used in calculating the number of shares in the computation of net loss per share for each of the periods set forth in the Statements of Operations. QUARTER ENDED AVERAGE LOSS MARCH 31, DAYS SHARES PER 1996: SHARES OUTSTANDING SHARES X DAYS OUTSTANDING LOSS SHARE 20,780,006 10 207,800,060 20,819,216 4 83,276,864 20,837,351 2 41,674,702 20,957,571 1 20,957,571 20,092,916 3 60,278,748 21,197,583 1 21,197,583 21,357,121 2 42,714,242 21,361,306 1 21,361,306 21,361,806 3 64,085,418 21,420,263 4 85,681,052 21,437,008 6 128,622,048 21,454,339 4 85,817,356 21,457,130 1 21,457,130 21,458,525 1 21,458,525 21,458,788 7 150,211,516 21,462,974 19 407,796,506 21,485,118 7 150,395,826 21,542,230 2 43,084,460 21,550,954 2 43,101,908 21,553,981 4 86,215,924 21,569,683 1 21,569,683 21,625,842 1 21,625,842 21,665,092 2 43,330,184 21,695,449 2 43,390,898 91 1,937,865,464 /91 21,295,225 (2,073,000) (0.10) Quarter Ended March 31, 1995: 10,404,951 2 20,809,902 10,429,951 2 20,859,902 10,443,208 82 856,343,056 10,464,925 4 41,859,700 90 939,872,560 /90 10,443,028 (2,009,000) (0.19)